Exagen Inc Stock Today
| XGN Stock | USD 3.56 0.21 6.27% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Exagen is selling at 3.56 as of the 16th of March 2025; that is 6.27 percent increase since the beginning of the trading day. The stock's open price was 3.35. Exagen has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of September 2019 | Category Healthcare | Classification Health Care |
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. The company has 17.9 M outstanding shares of which 32.45 K shares are at this time shorted by investors with about 0.17 days to cover. More on Exagen Inc
Moving together with Exagen Stock
Moving against Exagen Stock
Exagen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President, CEO | John Aballi | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Healthcare, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsExagen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Exagen's financial leverage. It provides some insight into what part of Exagen's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exagen Inc (XGN) is traded on NASDAQ Exchange in USA. It is located in 1261 Liberty Way, Vista, CA, United States, 92081 and employs 11 people. Exagen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 63.72 M. Exagen Inc runs under Biotechnology sector within Health Care industry. The entity has 17.9 M outstanding shares of which 32.45 K shares are at this time shorted by investors with about 0.17 days to cover.
Exagen Inc has about 76.39 M in cash with (13.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Exagen Probability Of Bankruptcy
Ownership AllocationExagen holds a total of 17.9 Million outstanding shares. Over half of Exagen's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Exagen Ownership Details
Exagen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 98.1 K | |
| Palumbo Wealth Management Llc | 2024-12-31 | 86.7 K | |
| Ubs Group Ag | 2024-12-31 | 64.2 K | |
| Nantahala Capital Management, Llc | 2024-12-31 | 62.1 K | |
| Penbrook Management Llc | 2024-12-31 | 44.6 K | |
| Wasatch Advisors Lp | 2024-12-31 | 43 K | |
| Creative Planning Inc | 2024-12-31 | 35.5 K | |
| State Street Corp | 2024-12-31 | 33.7 K | |
| Blackrock Inc | 2024-12-31 | 33.4 K | |
| Rtw Investments, Llc | 2024-12-31 | 1.5 M | |
| Cowen And Company, Llc | 2024-09-30 | 891.4 K |
Exagen Historical Income Statement
Exagen Stock Against Markets
Exagen Corporate Management
| Jeffrey Black | Chief Officer | Profile | |
| Debra Zack | Chief Officer | Profile | |
| John Wegener | Senior Marketing | Profile | |
| Ryan Douglas | Investors Officer | Profile | |
| Mark Hazeltine | Chief Officer | Profile | |
| MingChou Lee | Chief Officer | Profile |
Already Invested in Exagen Inc?
The danger of trading Exagen Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Exagen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Exagen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Exagen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets | Return On Equity |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.